Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1148-1156

  Tamatani, Tetsuya ^a   Ferdous, Tarannum ^a   Takamaru, Natsumi ^a   Hara, Kanae ^a   Kinouchi, Makoto ^a   Kuribayashi, Nobuyuki ^a   Ohe, Go ^a   Uchida, Daisuke ^a   Nagai, Hirokazu ^a   Fujisawa, Kenji ^a   Miyamoto, Youji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

5 fluorouracil; 5 fluorouracil metabolic enzymes; Docetaxel; Oral squamous cell carcinoma; Sequential treatment

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; FLUOROURACIL; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DIHYDROURACIL DEHYDROGENASE (NADP); DOWN-REGULATION; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; MOUTH NEOPLASMS; OROTATE PHOSPHORIBOSYLTRANSFERASE; TAXOIDS; THYMIDYLATE SYNTHASE; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865015481     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1544     Document Type: Article

References (34)

1. Azuma M, Harada K, Suprianto, Tamatani T, Motegi K, Ashida Y and Sato M: Potentiation of induction of apoptosis by sequential treatment with cisplatin followed by 5-fluorouracil in human oral cancer cells. Int J Oncol 24: 1449-1455, 2004.
2. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T and Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol (Suppl) 547: 25-29, 2002. (Pubitemid 34913460)
3. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 185: 278-284, 2003. (Pubitemid 36298898)
4. LoTempio MM, Veena MS, Steele HL, Ramamurthy B, Ramalingam TS, Cohen AN, Chakrabarti R, Srivatsan ES and Wang MB: Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 11: 6994-7002, 2005. (Pubitemid 41428759)
5. Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, Lefantzis D and Dokianakis G: Sequential chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24: 227-231, 2001. (Pubitemid 32520624)
6. Schrijvers D, Herpen CV, Kerger J, Joosens E, Laer CV, Awada A, Weyngaert VD, Nguyen H, Bouder CL, Castelijns JA, Kaanders J, Mulder PD and Vermorken JB: Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 15: 638-645, 2004. (Pubitemid 38559602)
7. Yamamoto S, Kurebayashi J, Kurosomi M, Kunisue H, Otsuki T, Tanaka K and Sonoo H: Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. Cancer Chemother Pharmacol 48: 233-238, 2001.
8. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407, 2006.
9. Ishikawa M, Miyauchi T and Kashiwagi Y: Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and ortate phosphoribosyl transferase activity level in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy. BMC Cancer 8: 188-194, 2008.
10. Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Sugito N, Mori R, Ogawa R, Katada T and Fujii Y: Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Esophagus 21: 15-20, 2008.
11. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K and Hirayama R: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791, 2003. (Pubitemid 36182616)
12. Taomoto J, Yoshida K, Wada Y, Tanabe K, Konishi K, Tahara H and Fukushima M: Overexpression of the ortate phosphoribosyl transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines. Oncology 70: 458-464, 2006. (Pubitemid 46333767)
13. Sakakura K, Chikamatsu K, Shino M, Sakurai T and Furuya N: Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome. Acta Otolaryngol 126: 1295-1302, 2006. (Pubitemid 44764329)
14. Kobayashi H, Koike T, Nakatsuka A, Kurita H, Sagara J, Taniguchi S and Kurashina K: Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma. Oral Oncol 41: 38-47, 2005. (Pubitemid 39647118)
15. Catimel G, Verwii J, Mattijssen V, Hanauska A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M and Kaye SB: Docetaxel (taxotere): an active drug for treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5: 533-537, 1994.
16. Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y and Fukushima M: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119: 783-791, 2006. (Pubitemid 44055889)
17. Ravdin PM, Burris HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E and Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995.
18. Tamatani T, Azuma M, Ashida Y, Yoshida H and Sato M: Enhanced radiosensitization and chemosensitization in NF-κB suppressed human oral cancer cells via the inhibition of γ-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 108: 912-921, 2004. (Pubitemid 38112622)
19. Honma K, Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K and Ochiya T: RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 14: 939-948, 2008.
20. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
21. Van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40: 939-950, 2004.
22. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV and Papotti M: Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14: 1059-1064, 2008. (Pubitemid 351302551)
23. Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M: Gene expression in colorectal cancer and in vitro chemosensitivity of 5-fluorouracil: a study of 88 surgical specimen. Cancer Sci 94: 633-638, 2003. (Pubitemid 36975020)
24. Yoo GH, Lin HS, Iskander AJ, Piechocki MP, Oliver J, Kewson D, Lonardo, F, Tainsky MA, Kim HR, Kim H and Ensley JF: Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study. Laryngoscope 115: 1938-1946, 2005. (Pubitemid 44391653)
25. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, Kewson D, Shibuya TY, Lonardo F and Tainsky MA: Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and powerblot. Clin Cancer Res 8: 3910-3921, 2002. (Pubitemid 35424786)
26. Ukon K, Tanimoto K, Shimokuni T, Noguchi T, Hiyama K, Tsujimoto H, Fukushima M, Toge T and Nishiyama M: Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells. Cancer Res 65: 1055-1062, 2005. (Pubitemid 40216468)
27. Bendardaf R, Ristamäki R, Syrjänen K and Pyrhönen S: Bcl-2 expression significantly correlates with thymidylate synthase expression in colorectal cancer patients. World J Gastroenterol 14: 6218-6223, 2008.
28. Shigematsu H, Yoshida K, Sanada Y, Osada S, Takahashi T, Wada Y, Konishi K, Okada M and Fukushima M: Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells. Int J Cancer 126: 2716-2725, 2010.
29. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H and O'Connell P: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23: 1169-1177, 2005. (Pubitemid 46202273)
30. Ford HER, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR and Jackman AL: Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD93311. Clin Cancer Res 8: 103-109, 2002. (Pubitemid 34101464)
31. Ahmed FY, Johnston SJ, Cassidy J, Kelly T, Binnie N, Murray GI, Gennip AH, Abeling NG, Knight S and McLeod HL: Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumours. J Clin Oncol 17: 2439-2445, 1999. (Pubitemid 29368243)
32. Mirjolet JF, Heyob MB, Didelot C, Peyrat JP, Abecassis J, Millon R and Merlin JL: Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 83: 1380-1386, 2000.
33. Domenech JD, Oliva C, Rovira A, Servat JC, Bosch M, Filella X, Montagut C, Tapia M, Campas C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J and Mellado B: Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12: 5578-5586, 2006. (Pubitemid 44497276)
34. Li J, Minnich DJ, Camp ER, Brank A, MacKay S and Hochwald SN: Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-κB. J Surg Res 132: 112-120, 2006.